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7. RENAL TRANSPLANTATION 
R. WElL and T. E. ST ARZL 
It has now been more than 40 years since the first 
attempt was made at human renal homotransplantation. 
The early efforts to apply this form of therapy to the 
treatment of terminal renal disease were likely to fail 
because they preceded an appreciation of the problems 
to be encountered. Knowledge of homograft rejection 
was scant and the therapy necessary to prevent this 
process was not understood at all. Since that time, a 
rational explanation of rejection has been provided by 
the studies of Medawar and other investigators. The 
evidence is overwhelming that rejection is due to im-
munologic repudiation of the alien tissue by the host. 
The intensity of this reaction is related to the degree of 
genetic dissimilarity between the donor and the reci-
pient. Its prevention depends to a greater or lesser 
extent on crippling the host's capacity for immunologic 
response to unfamiliar antigens. 
The initial attempts at potentiating homograft func-
tion by alteration of the host were made with total body 
irradiation. Such therapy proved to be of value for the 
prevention of rejection, but the requisite dosage was so 
high that most of the recipient patients died from bone 
marrow depression and sepsis. Despite the exhorbitant 
risk imposed, two patients from this pioneer era are still 
alive twenty years after transplantation by Murray of 
Boston and Hamburger of Paris with homografts from 
their fratenlal twins. Today there is no major center in 
the world using total body irradiation as an important 
element in transplantation therapy. 
In spite of the occasional early encouraging experi-
ence, the prospect of achieving significant clinical benefit 
from renal homotransplantation in more than the 
isolated case seemed remote indeed except when an 
identical twin (isograft) donor was available, until the 
discovery by Schwartz and Dameshek of the immuno-
suppressive properties of 6-mercaptopurine in 1959, 
and the subsequent testing of this drug and its analogue, 
azathioprine, by Caine and Zukoski. It then seemed that 
prevention of homograft rejection could be accom-
plished with greater regularity and with less risk to the 
recipienl than had been possible with total body irradia-
tion. Long-term homograft· viability was achieved in 
animals without the appearance of concomitant host 
leokopenia or agranulocytosis. During the ensuing 
several years, clinical efforts at homotransplantation of 
the kidney proceeded such that by 1979, more than 
40 000 such potentially therapeutic operations had been 
performed throughout the world. 
CANDIDATES FOR HOMOTRANSPLANT A TION 
The general requirements for candidacy are simple: 
the patient should have irreversible renal disease from 
which life expectancy without dialysis or transplantation 
is limited to a few weeks or months. More subtle 
indications for renal transplantation occasionally need to 
be considered. For example, kidneys have been given to 
patients with completely normal renal function who were 
suffering from Fabry's disease, an inborn error of meta-
bolism characterized by a deficiency of the enzyme 
ceramide trihexosidase and a consequent inability to 
hydrolyse the terminal galactose of ceramide trihex-
oside, which therefore accumulates in various tissues. 
The objective of renal transplantation in such cases is not 
to replace specific organ function but rather to provide a 
source of enzyme manufacture. 
Just a few years ago, an obligatory condition for renal 
homotransplantation was a normal lower urinary tract. 
More recently it has been found possible to successfully 
implant homograft ureters to seriously diseased blad-
ders, to correct mechanical bladder abnormalities before 
or simultaneously with transplantation, or in some irist-
ances to perform transplantation with urinary drainage 
into an intestinal conduit. 
The requirements have relaxed for admission to trans-
plantation programs in other respects as well. Whereas 
serious disease in other organ systems used to rule out 
renal transplantation, this position is no longer support-
able. Finally, the age ceiling has been rising steadily. It is 
still true that transplantation is best tolerated by the 
relatively young. Nevertheless, increasing numbers of 
recipients have been treated in their 40s, 50s and even 
60s. 
Very frequently an interim period of intensive resus-
citative therapy is mandatory before a decision for or 
against transplantation can be made. On many occasions 
a prospective recipient has entered the hospital in acute 
heart failure with severe hypertension, anasarca, or with 
a variety of neurologic complications including profound 
coma. In most instances these findings can be rapidly 
reversed by the institution of emergency dialysis. If this 
proves impossible, the likelihood of subsequent success-
ful transplantation is reduced. A significant improve-
ment is often necessary prior to operation in order for 
the patient to have a reasonable chance of tolerating the 
trauma of surgery and the stress of the I?ost-operative 
period. 
DONOR SELECTION 
Renal tissue is available from three general sources. 
First, there is now ample evidence that cadaveric kidneys 
often provide good function. A variable degree of dam-
age is inevitable in the terminal pre mortem state of the 
donor, to which is added an additional devascularized 
period during removal and transfer. The harmful effects 
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of the ischemic time can be considerably minimized by 
quickly cooling the kidney after its excision. In recent 
years legislation supporting the concept of neurologic 
death has greatly improved the quantity and quality of 
cadaver kidneys available for transplantation. but the 
need still far exceeds the supply. 
Volunteer living donors provide a second source of 
renal homografts. Here. the entire procedure for both 
donor and recipient can be planned in advance and 
executed with precision. The transplanted kidneys 
almost invariably work well immediately after operation. 
since the donors are in good health. the ischemic inter-
vals are short. and in addition the homografts can be 
further protected. just as with cadaveric kidneys, by 
perfusion with a cold electrolyte solution immediately 
after removal. 
Finally, it may ultimately become possible to use renal 
heterografts obtained from subhuman primate donors. 
Efforts have been made to transplant Rhesus, baboon. 
and chimpanzee kidneys to man, with surprisingly good 
and unexpectedly persistent function. The Rhesus heter-
ograft transplanted by Reemtsma excreted urine in its 
human environment for almost a week. and the baboon 
kidneys used at the University of Colorado functioned 
for as long as 2 months. One of Reemtsma's patients. 
who received a pair of chimpanzee kidneys, survived 
with good to fair renal function for 9 months. Despite 
these encouraging notes all 20 patients treated with 
various heterografts are now dead, and it seems unlikely 
that consistent success can be obtained with currently 
available immunosuppressive methods. 
The source of the transplanted tissue has to date been 
the most important biologic determinant of success or 
failure. The best results have been when blood relatives 
have provided the homografts, as will be described in a 
subsequent section. Non-relative donors have been less 
satisfactory, and the poorest results have been with 
heterografts. In all classes, however, the outcome is still 
unpredictable in the individual case. Violent and uncon-
trollable rejection episodes have occurred with familial 
homografts. Conversely, non-related homografts or 
even chimpanzee heterografts have on occasion incited 
little clinically detectable host reaction. 
These findings suggest that a wide spectrum of donor-
recipient histocompatibility exists with employment of 
any of these donor pools. Quantitation of histocompati-
bility factors in the human has not been possible in a 
precise way, in spite of the efforts of a number of 
investigators. When such techniques _become available, 
it will be possible to match the prospective recipient with 
the most appropriate donor, thereby eliminating much 
of the guesswork in donor selection. 
Blood Group Considerations 
When possible. donors and recipients are selected of 
the same ABO blood groups. This is not essential, 
however. Various mismatch combinations appear not to 
carry an increased risk providing the transplant is not 
placed into a recipient whose plasma contains preformed 
jIemagglutinins directed agatnst red cell antigens ~hicl 
. are present in the renal cells of patients who belong tI 
blood groups A. B. and AB. For example. a person 0 
'0' type can provide a kidney for a recipient of any bluo( 
group since the renal tissue of such a donor does no 
contain A or B isoantigens which could bind witt 
hemagglutinins present i"il recipients of A, B, or C 
group. The 0 patient is thus the universal donor 
Because the kidney of an individual with AB blooe 
contains both A and B isoantigens. he could safel} 
donate only to an AB recipient. Conversely, an AE 
patient could accept a kidney from any donor (universal 
recipient) since his plasma does not contain anti-A OJ 
anti-B hemagglutinins. The rules of tissue transfer across 
blood group barriers are. therefore, the same as those 
which apply to the use of non-matched blood in blood 
banks (Table 1). It is noteworthy that long survival has 
TABLE 1 
DIRECTION OF ACCEPTABLE ~fpMArCeba TISSLE TRANSFER" 
o to non-O Safe 
Rh- to Rh+ Safe 
__ R_h_+_to_R_h_-__________ R_e_la_tively safe 
A to non-A Dangerous 
B to non-B Dangerous 
AS to non-AS Dangerous 
"0 is universal donor, AS is universal recipient 
been obtained despite violation of this scheme. One 
patient at the University of Colorado has normal renal: 
function 17 years after B to A homotransplantation.' 
Nevertheless, a number of immediate failures have 
occurred after similar mismatches, probably because oft 
antibody-mediated hyperacute rejection. ' 
SURGICAL TECHNIQUES 
Both the donor and recipient operations involve the 
use of standard surgical techniques. Donor nephrectomy 
must be done with greater care than nephrectomy for: 
renal disease in order to provide undamaged vessels and 
ureter for anastomosis. When living donors are used. it is 
important to perform pre-operative renal arteriography 
to determine if there are anomalies of blood supply: 
which might preclude donation. Arteriography is less 
important for cadaver kidney harvesting. where a large, 
incision can readily reveal vascular anomalies and where ,: 
at least _one of the two kidneys is usually anatomically 
suitable for transplantation. : 
The recipient operation is 'usually quite simple. Ordi- ' 
narily, the kidney is placed in the iliac fossa contralateral i 
to its donor location. reversing the anterioposterior 
relationships of the hilar structures (Fig. 1). In this way 
the ureter and pelvis are anterior, the renal artery in an . 
intermediate position, and the renal vein posterior. The 
host hypogastric artery and external iliac vein are con-
nected to the renal vessels; urinary drainage is provided 
by performing ureteroneocystostomy or occasionally 
ureteroureterostomy . Under vanous circumstances 
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FIG. \. Vsual method of renal homotransplantation, Depicted is the 
donor left kidney transplanled 10 Ihe recipient's right iliac fossa. 
modifications of this technique are necessary either 
because of the small size of the recipient, or because of 
disease in the iliac vessels. It is sometimes necessary to 
remove the recipient's own diseased kidneys either at the 
time of transplantation or at a separate operation. This 
can easily be done through a short upper midline inci-
sion. Under these circumstances. splenectomy is usually 
performed at our center. and splenectomy alone is 
sometimes done if there is pretransplantation evidence 
of marked hypersplenism. 
If a technically successful homotransplantation is car-
ried out. there is an early postoperative diuresis. In 
unusual cases this has exceeded 500 ml per hour with the 
resultant need for meticulous management of fluid and 
electrolyte replacement. With restoration of renal func-
tion there is dramatic improvement in the patient's 
gene ral condition. 
THE EVENTS OF REJECTION 
The most useful agents for the prevention of rejection 
have been azathioprine, cyclophosphamide. prednisone, 
and heterologous antilymphocyte globulin (ALG). 
Although these agents diminish the strength of rejection. 
they frequently do not altogether prevent its occurrence. 
A typical example of homograft rejection in a patient 
receiving immunosuppression is illustrated in Fig. 2. 
There was excellent renal function for more than two 
weeks after receipt of a homograft from his younger 
brother. His convalescence was then interrupted by an 
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FIG. 2, ClaSSical rejectIOn cnsls In a pallent trealed in lY63 I'onh the double drug 
combination of azathiopnne (lmuran) and prednisone Deterioration of 
renal function began 17 days after transplantation, All sl1gmata of relection 
are present except for acute h~pertcnsion and "'eight gain. which "'ere 
successfully prevented by medical treatment. The palient. .. hose trans· 
plantation was on 17 April. 1963. still has excellent function of the same 
homograft almost 17 years later. Biopsy of the homograft after two years was 
normal. Anti-C = actinomycin C; LN = left nephrectomy at the time of 
transplantation; R.'I = right nephrectomy. 
abrupt drop in creatinine clearance, relative oliguria. a 
secondary rise in blood-urea nitrogen, fever, and pro-
teinuria. The addition of prednisone to pre-existing 
therapy with azathioprine was followed by a reversal of 
all these adverse findings_ 
The demonstration that most rejection episodes could 
be reversed was a fundamental disclosure which made 
clinical homotransplantation a practical possibility. In 
addition, it is clear that the drastic immunosuppressive 
measures frequently required for reversal of rejection 
are not needed permanently. Thus. in the patient de-
scribed (Fig. 2). the large doses of prednisone which 
were temporarily necessary could be quickly reduced. 
and in this case they were discontinued altogether within 
5 months. The patient still has perfect renal function 
almost 17 years post-transplantation. Such observations 
suggest that some alteration occurs in the relationship 
between the homograft and the host with the passage of 
time which diminishes the difficulty. of controlling rejec-
tion. Whether this change occurs in the homograft or in 
the host. or both. is not certain. 
Clinical Immunosuppression 
(See also p. 70) 
Drug Combinations 
In 1962. in what has been termed the beginning of the 
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FIG. 3. The course of a patient who received antilymphocyte globulin (ALG) before and for the first four months after renal 
homotransplantation. The donor was an older brother. There was no early rejection. Prednisone therapy was started 40 days 
post-operatively because of high rises in the serologic titres which indicated a host response against the injected foreign protein and which 
warned against a possible anaphylactic reaction. Note the insidious onset of late rejection after cessation of globulin therapy. This was 
treated by increasing the maintenance dose of steroids. (By permission of Surg. Gynec. Obstet. 126: 1023, 1968). 
modern era of transplantation, the double drug com-
bination of azathioprine and prednisone -was introduced 
as the cornerstone of immunosuppressive therapy. In 
1966, heterologous antilymphocyte globulin (ALG) 
raised in the horse against human lymphoid tissue was 
added in the formulation of a triple drug program. The 
concept was that the ALG should be restricted to the 
early post-operative course when there was the greatest 
risk of rejection, and that with the hoped-for 'accept-
ance' of the transplant the globulin could be safely 
discontinued within a few weeks or months (Fig. 3). The 
value of anti-lymphocyte or anti thymocyte globulin 
(ATG) in clinical transplantation, after 13 years of use in 
human kidney transplantation, is still argued, partly 
because of the difficulty of consistently manufacturing 
this biologic product with reliable immunosuppressive 
potency. Nevertheless, when high potency ALG or A TG 
can be produced, it is beneficial to the patient. 
In the early 1970s a new kind of triple drug therapy 
was extensively evaluated, in which the alkylating agent, 
cyclophosphamide, was substituted for the purine ana-
logue, azathioprine (Fig. 4). Even though these drugs 
are of different chemical classes and act at different 
phases of the cell cycle, they have proved to be about 
equally effective and, therefore, essentially interchange-
able in triple drug treatment. Since 1972 we have re-
turned to using azathioprine rather than cyclophospha-
mide for most patients because of our general satisfac-
tion with azathioprine, because cyclophosphamide's 
effect on bone marrow is more difficult to predict, an( 
because cyclophosphamide is more likely to cause bald 
ness, azospermia, and hemorrhagic cystitis. 
Thymectomy and Splenectomy 
Although the above therapeutic methods are of mOTl 
or less unquestioned value, two other biological man 
ipulations of less certain value have been carried out ir 
some cases. 
Between 1962 and 1966, thymectomy was performe( 
prior to transplantation, primarily because of the evi 
dence in rodent experiments by Miller that the thymm 
gland is important in the adult in re-establishing reactiv· 
ity to foreign antigens after a period of immunologica 
depression. Follow-ups of more than 5 years for all those 
recipients, including in each instance samples of the 
renal homografts obtained either by autopsy or biopsy. 
showed that the histopathologic abnormalities in these 
kidneys were significantly less than in comparable 
patients whose thymus glands were not disturbed. In 
spite of this finding, which was the first evidence fOJ 
potential function of the adult human thymus, patient 
survival was not beneficially influenced by thymectomy. 
Since complete thymic excision can be a formidable 
undertaking in uremic humans, this ancillary procedure 
is not currently being performed in our patients. 
The rationale for splenectomy is that the spleen par-
ticipates in the immunologic response to intravenous 
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FIG. 4. The first 60 days after the transplantation of a kidney from a mother to her daughter. Although the rejection 
crisis after a week was a severe one, it was easily and completely reversed. Note that leukopenia was never 
produced by the daily doses of cyclophosphamide that were usually between 0·5 to 1·0mg per kg/day. 
ALG = horse antilymphocyte globulin; BUN = blood Ul"ea nitrogen; CCr = creatinine clearance; WBC = white 
blood cell count; Arrow = 625 mg methylprednisolone intravenously. (By permission of Surg. Gynec. Obslel. 
133: 981, 1971). -
antigen. There is no proof that splenectomy improves 
survival after renal transplantation, but unlike 
thymectomy, splenectomy is a simple procedure that 
does not require a separate operation. Consequently, we 
continue to perform splenectomy in many of our 
patients, particularly those whose pre transplantation 
peripheral white blood counts are consistently below 
5000 per cubic millimeter. 
Thoracic Duct Drainage 
The immunosuppressive effect of thoracic duct drain-
age has been known for at least fifteen years. Trials with 
kidney transplant patients in Sweden, Boston, and Texas 
suggested that the procedure was valuable, but the 
technical difficulty of keeping the drainage system patent 
and uninfer.::ted probably contributed to the abandon-
ment of this method, except at Vanderbilt University in 
Tennessee. 
Since February, 1978, using a Swan-Ganz double 
lumen catheter with constant heparin catheter flushing, 
it has been possible at our center to maintain thoracic 
duct fistula drainage for several weeks in more than 90% 
of patients, and for more than three months in selected 
patients with chronic high-titers of preformed anti-
bodies. The precise mechanism of immunosuppressive 
action of this technique is not clear; but it is usually 
possible to remove at least one billion lymphocytes daily, 
and serum immunoglobulin G levels fall. 
Although the volume of thoracic duct drainage, up to 
twelve liters per day, imposes logistical problems, it has 
been a very feasible and safe adjunct to the previous 
triple drug regimen. 
Toxicity of Immunosuppressive Agents 
Although they are essential for maintenance of 
homograft function, the agents used to protect the 
homograft do so by rendering the patient more suscepti-
ble to a variety of inimical antigens. It is not surprising, 
therefore, that most of the early deaths after homotrans-
plantation are due to complications of the agents used. A 
characteristic although not common lethal sequence of 
events is shown in Fig. 5. The young man concerned 
received a kidney from his brother. After 10 days of 
good homograft function a severe rejection crisis occur-
red with anuria. The rejection was reversed but after 
renal function had returned, the patient became 
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FIG. 5. Typical unsuccessfully treated case. The donor and recipient were 
brothers. both of A blood type. A violent rejection crisis followed good early 
function. and anuria developed which lasted two weeks. Although the rejec-
tion was reversed and a secondary diuresis began. the patient died from drug 
toxicity. leukopenia. and septicemia. Anti-C = Each arrow is 200 I'g in-
travenous actinomycin C. 
leukopenic and died of a fungus and bacterial blood 
stream infection. This complication was due to overdos-
age with azathioprine. The same kind of bone marrow 
depression could be caused by cyclophosphamide. In 
recent years. early deaths caused by excessive quantities 
of these cytotoxic drugs have been virtually eliminated. 
At a later time, continuing immunosuppression, parti-
cularly if large maintenance doses of prednisone are 
required, can lead to infection with opportunistic micro-
organisms for which highly specific antibiotic therapy is 
often not available. Typically, these infections occur 
despite adequate peripheral white blood cell counts, and 
are caused predominantly by fungi, protozoa, and 
viruses. Bacteria that ordinarily have low pathogenicity 
such as Listeria monocytogenes are also seen with in-
creased frequency _ One of the most serious public health 
hazards resulting from transplantation has been the 
creation of virus hepatitis reservoirs. Between 10 and 
20% of chronically surviving recipients of renal homo-
grafts come to have the Australia antigen in their serum 
which, once identified, tends to be a permanent finding. 
Even though liver function tests may be normal, these 
patients are hepatitis carriers and are capable of infect-
ing other patients or members of the staff. 
An increased susceptibility to infection is not the only 
penalty to chronic immunosuppression. :--;umerous de 
novo malignancies have been reported in chronically 
surviving recipients of renal homografts. In our own 
center. almost 6% of the patients have developed a 
carcinoma or a Iymphoreticular neoplasm. The develop-
ment of this striking complication may represent an 
unwelcome clinical confirmation of Burnet's surveillance 
hypothesis, which holds that the immune system is 
normally responsible for the identification as 'non-self 
and the elimination of mutant cells. Fortunately the 
commonest malignant neoplasm in kidney transplant 
patients is highly curable squamous cell carcinoma of the 
skin. 
In addition to its contribution to the foregoing side-
effects, prednisone causes facial and other changes 
which are an annoyance to most patients whose late 
renal function is dependent upon continuing steroid 
therapy. Aseptic necrosis of bone and lens cataracts have 
also been observed. 
It should be emphasized that the increased risks of 
infection and malignancy do not vitiate the value of 
transplantation procedures. The infections and the neo-
plasms can usually be controlled. 
Late Rejection 
As mentioned above, the necessity for intensive im-
munosuppressive therapy tends to decrease late after 
transplantation, and a number of patients have now been 
living for many years with no clinical evidence of im-
munological activity directed against the homograft. 
Nevertheless, a significant number of lorig-term survi-
vors have had manifestations of late rejection, some-
times in a form which resembles that seen early after 
operation. These late 'crises' have proved to be partially 
reversible with the resumption of large steroid doses. In 
such patients, the homograft function can be main-
tained, but the need for continuous high dose steroid 
therapy constitutes a threat to a long life expectancy. A 
more subtle form of late rejection without functional 
manifestations may be going on in some homografts. 
Kidneys biopsied or recovered at autopsy one to two 
years after homotransplantation frequently contain focal 
aggregates of mononuclear cells, a variety of vascular 
lesions in both the large and small vessels, lesions of the 
glomerular basement membrane, and patchy interstitial 
fibrosis. These morphologicall)( damaged homo grafts 
may function in a satisfactory way for many years. 
However, they clearly do not have an indefinite func-
tionallife expectancy, and such grafts have failed as late 
as 8 or 9 years after their insertion. 
Results and Future Prospects 
It is not the purpose of this chapter to present clinical 
data. Nevertheless, a brief statement is in order about 
what has been achieved so far. The modern era of 
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whole-organ transplantation began in late 1962"and early 
1963. from which era there are still about two dozen 
living patients who have had continuous function of their 
original transplants. Since this time. thousands of 
patients have benefited from renal homotransplantation 
and have therefore undergone relatively complete social 
and vocational rehabilitation. This has been particularly 
true in recipients of consanguineous grafts who now can 
expect to survive the first post-transplantation year at 
the rate of approximately 90% (Fig. 6). It is less true of 
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FIG. 6. Life survival curves of patients treated with primary related 
homografts during five intervals from 1962 to the summer of 1972. 
Arrows show time of minimum follow.up. (By permission of Trans· 
plantation Proceedings IX: 1. 1977.) 
recipients of unrelated (cadaveric) transplants in whom 
only approximately 50% of grafts function for as long as 
a year. After one year the loss rate of grafts and patients 
has proved to be at a very slow rate in consanguineous 
cases. With non-related donors the outlook after one 
year is less optimistic. There is frequently a need for 
retransplantation especially in cadaveric cases. With 
both kinds of donors, the experience of the last decade' 
has shown renal homotransplantation to be an excep-
tionally effective form of palliative treatment for patients 
with terminal renal disease. 
Our recent experience with thoracic duct drainage 
suggests that this fourth immunosuppressive - method, 
added to corticosteroid, azathioprine, and antilympho-
cyte globulin. will permit a higher level of patient 
survival than was previously feasible using only three 
agents. Our preliminary results using this quadruple 
agent approach In recipients of first cad;ner kidneys. 
with short follow-up times of only 3-12 months and with 
R early retransplants. are only I death in this group of 27 
patients. and 89lJc (24/27) of these patients currently 
have functioning transplants. In a small number of cases 
using pretransplantation thoracic duct drainage. success-
ful kidney transplantation has been possible in spite of 
high titers of preformed antibodies in the recipient and 
in spite of strongly positive direct cytotoxic crossmatches 
between the recipient and the specific donor of the 
cadaver kidney. The reduction in serum immunoglobu-
lins caused by preoperative thoracic duct drainage for 
one or two months probably has had some influence on 
the avoidance of hyperacute rejection. which otherwise 
would have been expected. 
The research and clinical experience with renal 
homotransplantation has direct application to the trans-
plantation of other organs. The immunosuppressive 
techniques developed with the kidney model have made 
possible the successes that have been achieved with 
hepatic and cardiac transplantation. There are a number 
of reasons for failure after transplantation of extrarenal 
organs, but for the most part these reasons are non-
immunologic. They include greater technical difficulties; 
the lack of artificial organs comparable to renal dialysis 
which could tide the hepatic, cardiac or pulmonary 
patient over transient periods of poor function; and a 
lack of discriminating techniques to diagnose rejection in 
its early and most reversible phases. 
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